Daroszewska A et al. |
Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. |
2004 |
J. Bone Miner. Res. |
pmid:15312251
|
Liu JM et al. |
[The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75]. |
2004 |
Zhonghua Nei Ke Za Zhi |
pmid:15312444
|
Jacobson A et al. |
Vitamin A differentially regulates RANKL and OPG expression in human osteoblasts. |
2004 |
Biochem. Biophys. Res. Commun. |
pmid:15313187
|
Ishida M and Amano S |
Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation. |
2004 |
J. Bone Miner. Metab. |
pmid:15316862
|
Jeffcoate W |
Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link? |
2004 |
Diabetologia |
pmid:15322748
|
Liu Z et al. |
Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae. |
2004 |
Protein Pept. Lett. |
pmid:15327363
|
Politou M et al. |
Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). |
2004 |
Br. J. Haematol. |
pmid:15327520
|
Erdogan B et al. |
Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. |
2004 |
Neurol. Res. |
pmid:15327755
|
Wada N et al. |
Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. |
2004 |
Bone |
pmid:15336598
|
Amato G et al. |
High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. |
2004 |
Bone |
pmid:15336617
|
Ono Y et al. |
Suppressive effect of Kanzo-bushi-to, a Kampo medicine, on collagen-induced arthritis. |
2004 |
Biol. Pharm. Bull. |
pmid:15340228
|
Sato N et al. |
MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. |
2004 |
J. Exp. Med. |
pmid:15353553
|
Wang L et al. |
Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34). |
2004 |
J. Bone Miner. Res. |
pmid:15355561
|
Nyambo R et al. |
Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. |
2004 |
J. Bone Miner. Res. |
pmid:15355567
|
Roux S and Mariette X |
The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression. |
2004 |
Leuk. Lymphoma |
pmid:15359989
|
Wittrant Y et al. |
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. |
2004 |
Biochim. Biophys. Acta |
pmid:15363860
|
Miyazaki T et al. |
Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. |
2004 |
J. Cell. Biochem. |
pmid:15372622
|
Tian QX and Huang GY |
[Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts]. |
2004 |
Zhongguo Yi Xue Ke Xue Yuan Xue Bao |
pmid:15379268
|
Nitta K et al. |
Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. |
2004 |
Am. J. Kidney Dis. |
pmid:15384019
|
Mizutani Y et al. |
Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. |
2004 |
Cancer |
pmid:15386310
|
Burton DW et al. |
Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. |
2005 |
Prostate |
pmid:15389781
|
Abu-Amer Y et al. |
TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. |
2004 |
J. Cell. Biochem. |
pmid:15389885
|
Smith MD |
Comment on review on T cells in bone biology. |
2004 |
Rheumatology (Oxford) |
pmid:15448222
|
Liu JM et al. |
Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. |
2005 |
Calcif. Tissue Int. |
pmid:15455183
|
Boabaid F et al. |
Leucine-rich amelogenin peptide: a candidate signaling molecule during cementogenesis. |
2004 |
J. Periodontol. |
pmid:15455742
|
Collantes Estévez E and González DomÃnguez J |
[Bone Paget's disease in the young adult]. |
2004 |
Rev Clin Esp |
pmid:15456600
|
Wise GE et al. |
Regulation of secretion of osteoprotegerin in rat dental follicle cells. |
2004 |
Eur. J. Oral Sci. |
pmid:15458504
|
Kitaura H et al. |
Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. |
2004 |
J. Immunol. |
pmid:15470024
|
Notoya M et al. |
Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells. |
2004 |
Biochem. Biophys. Res. Commun. |
pmid:15474477
|
Yip KH et al. |
Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity. |
2004 |
J. Bone Miner. Res. |
pmid:15476591
|
Dai SM et al. |
Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. |
2004 |
Ann. Rheum. Dis. |
pmid:15479886
|
Wang JC et al. |
Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). |
2004 |
Exp. Hematol. |
pmid:15504545
|
Boabaid F et al. |
The role of parathyroid hormone-related protein in the regulation of osteoclastogenesis by cementoblasts. |
2004 |
J. Periodontol. |
pmid:15515341
|
Franck H et al. |
Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. |
2004 |
J. Rheumatol. |
pmid:15517638
|
Ueland T |
Bone metabolism in relation to alterations in systemic growth hormone. |
2004 |
Growth Horm. IGF Res. |
pmid:15519248
|
Vidal K et al. |
Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. |
2004 |
Am. J. Physiol. Gastrointest. Liver Physiol. |
pmid:15521102
|
Chen Q et al. |
Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. |
2004 |
Horm. Metab. Res. |
pmid:15523591
|
Grigorie D et al. |
Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. |
2003 |
Rom J Intern Med |
pmid:15526523
|
Saidenberg-Kermanac'h N et al. |
TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. |
2004 |
Bone |
pmid:15542046
|
Ueland T et al. |
Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. |
2004 |
J. Am. Coll. Cardiol. |
pmid:15542278
|
Demer LL and Abedin M |
Skeleton key to vascular disease. |
2004 |
J. Am. Coll. Cardiol. |
pmid:15542279
|
Franchimont N et al. |
Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. |
2004 |
Clin. Exp. Immunol. |
pmid:15544627
|
Ketteler M et al. |
"Missing" inhibitors of calcification: general aspects and implications in renal failure. |
2005 |
Pediatr. Nephrol. |
pmid:15549415
|
Ichinose Y et al. |
Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading. |
2004 |
Calcif. Tissue Int. |
pmid:15549649
|
Kanzaki H et al. |
Local OPG gene transfer to periodontal tissue inhibits orthodontic tooth movement. |
2004 |
J. Dent. Res. |
pmid:15557398
|
Zhang X et al. |
Synovial fibroblasts infected with Salmonella enterica serovar Typhimurium mediate osteoclast differentiation and activation. |
2004 |
Infect. Immun. |
pmid:15557643
|
Theoleyre S et al. |
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. |
2004 |
Cytokine Growth Factor Rev. |
pmid:15561602
|
Mori T et al. |
RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. |
2004 |
Nucleic Acids Res. |
pmid:15562003
|
Oh ES et al. |
Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. |
2005 |
Metab. Clin. Exp. |
pmid:15562379
|
Ling JQ and Li JP |
[Insulin-like growth factor-II and basic fibroblast growth factor affect periodontal ligament cells expressing osteoprotegerin in vitro]. |
2004 |
Hua Xi Kou Qiang Yi Xue Za Zhi |
pmid:15562643
|
Collin-Osdoby P |
Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. |
2004 |
Circ. Res. |
pmid:15564564
|
Neville-Webbe HL et al. |
Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. |
2004 |
Breast Cancer Res. Treat. |
pmid:15567943
|
Rhee EJ et al. |
Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. |
2005 |
Clin. Sci. |
pmid:15569000
|
Fang TY et al. |
[Serum osteoprotegrin and serum bone gamma-carboxyglutamine acid-containing protein are correlated with bone mineral density in normal women]. |
2004 |
Zhonghua Yi Xue Za Zhi |
pmid:15569454
|
Atkins GJ et al. |
Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. |
2005 |
J. Cell. Physiol. |
pmid:15573398
|
Masui T et al. |
Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. |
2005 |
Biomaterials |
pmid:15576143
|
Herrmann M and Herrmann W |
The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. |
2004 |
Clin. Chem. Lab. Med. |
pmid:15576300
|
Jono S |
[Risk factors of atherosclerosis in end-stage renal disease patients]. |
2004 |
Clin Calcium |
pmid:15576949
|
Shimizu M and Tamura T |
[Regulation of bone mineralization by parathyroid hormone]. |
2004 |
Clin Calcium |
pmid:15577058
|
Ogata H et al. |
[Prophylaxis and treatment of adynamic bone]. |
2004 |
Clin Calcium |
pmid:15577107
|
Manganelli P et al. |
OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? |
2005 |
Clin. Rheumatol. |
pmid:15583970
|
Wang L et al. |
Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. |
2005 |
Am. J. Physiol. Endocrinol. Metab. |
pmid:15585587
|
Byrne FR et al. |
CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. |
2005 |
Gut |
pmid:15591508
|
Lee CK et al. |
Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. |
2004 |
Arthritis Rheum. |
pmid:15593184
|
Zhang D et al. |
[Expression of OPG and RANKL at protein level in human periodontal ligament cells and the effect of 1alpha,25(OH)(2) vitamin D(3) on the secretion of OPG protein in vitro]. |
2004 |
Beijing Da Xue Xue Bao |
pmid:15605102
|
Rajzbaum G et al. |
French women, fractures and aortic calcifications. |
2005 |
J. Intern. Med. |
pmid:15606383
|
Chondrogianni N et al. |
Cloning of differentially expressed genes in skin fibroblasts from centenarians. |
2004 |
Biogerontology |
pmid:15609104
|
Martinetti A et al. |
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. |
2004 |
Endocr. Relat. Cancer |
pmid:15613451
|
Whyte MP and Mumm S |
Heritable disorders of the RANKL/OPG/RANK signaling pathway. |
2004 |
J Musculoskelet Neuronal Interact |
pmid:15615493
|
Hofbauer LC et al. |
The OPG/RANKL/RANK system in metabolic bone diseases. |
2004 |
J Musculoskelet Neuronal Interact |
pmid:15615494
|
Ritchlin CT et al. |
RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. |
2004 |
J Musculoskelet Neuronal Interact |
pmid:15615495
|
Clohisy DR and Mantyh PW |
Bone cancer pain and the role of RANKL/OPG. |
2004 |
J Musculoskelet Neuronal Interact |
pmid:15615497
|
Sakai A et al. |
Osteoclast development in immobilized bone is suppressed by parathyroidectomy in mice. |
2005 |
J. Bone Miner. Metab. |
pmid:15616888
|
Sasaki N et al. |
Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). |
2005 |
J. Bone Miner. Metab. |
pmid:15616893
|
Belibasakis GN et al. |
The cytolethal distending toxin induces receptor activator of NF-kappaB ligand expression in human gingival fibroblasts and periodontal ligament cells. |
2005 |
Infect. Immun. |
pmid:15618171
|
Liu XH et al. |
Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. |
2005 |
Endocrinology |
pmid:15618359
|
Cao JJ et al. |
Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44. |
2005 |
J. Bone Miner. Res. |
pmid:15619667
|
Liu PY et al. |
A randomized placebo-controlled trial of short-term graded transdermal estradiol in healthy gonadotropin-releasing hormone agonist-suppressed pre- and postmenopausal women: effects on serum markers of bone turnover, insulin-like growth factor-I, and osteoclastogenic mediators. |
2005 |
J. Clin. Endocrinol. Metab. |
pmid:15623811
|
Zehnder AF et al. |
Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. |
2005 |
Laryngoscope |
pmid:15630389
|
Kees M et al. |
Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera. |
2005 |
Thromb. Haemost. |
pmid:15630493
|
Grzegorzewska AE and MÅ‚ot M |
Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. |
2004 |
Rocz. Akad. Med. Bialymst. |
pmid:15631341
|
Grzegorzewska AE and MÅ‚ot M |
Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. |
2004 |
Rocz. Akad. Med. Bialymst. |
pmid:15631342
|
Mochizuki S et al. |
[Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis]. |
2005 |
Clin Calcium |
pmid:15632471
|
Naumnik W et al. |
Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer. |
2004 |
Rocz. Akad. Med. Bialymst. |
pmid:15638385
|
Oh KW et al. |
Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. |
2005 |
Clin. Endocrinol. (Oxf) |
pmid:15638876
|
Marotte H et al. |
Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. |
2005 |
Arthritis Res. Ther. |
pmid:15642135
|
Katsuyama H et al. |
Menaquinone-7 regulates the expressions of osteocalcin, OPG, RANKL and RANK in osteoblastic MC3T3E1 cells. |
2005 |
Int. J. Mol. Med. |
pmid:15647836
|
Altun A et al. |
Decreased serum osteoprotegerin levels in patients with cardiac syndrome X. |
2004 |
J. Endocrinol. Invest. |
pmid:15648548
|
Matayoshi T et al. |
Neuropeptide substance P stimulates the formation of osteoclasts via synovial fibroblastic cells. |
2005 |
Biochem. Biophys. Res. Commun. |
pmid:15649411
|
Lukić IK et al. |
Alteration of newly induced endochondral bone formation in adult mice without tumour necrosis factor receptor 1. |
2005 |
Clin. Exp. Immunol. |
pmid:15654822
|
Subramaniam M et al. |
TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro. |
2005 |
Mol. Cell. Biol. |
pmid:15657444
|
Sato K |
[Osteoclast-activating factors (OAF)]. |
2004 |
Nippon Rinsho |
pmid:15658306
|
Kiviranta R et al. |
Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. |
2005 |
Bone |
pmid:15664014
|
Avbersek-Luznik I et al. |
Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? |
2005 |
Nephrol. Dial. Transplant. |
pmid:15665031
|
Bhatia P et al. |
Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. |
2005 |
Clin. Cancer Res. |
pmid:15671541
|
Kiefer JA et al. |
The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. |
2004 |
Clin. Exp. Metastasis |
pmid:15672862
|
Rassi CM et al. |
Modulation of osteoclastogenesis in porcine bone marrow cultures by quercetin and rutin. |
2005 |
Cell Tissue Res. |
pmid:15688188
|
Haynes DR |
Bone lysis and inflammation. |
2004 |
Inflamm. Res. |
pmid:15693607
|
Olesen P et al. |
Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. |
2005 |
Diabetologia |
pmid:15700136
|
Silvestrini G et al. |
Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. |
2005 |
J. Mol. Histol. |
pmid:15704000
|